Neurent Medical

History

2021: Attraction of $25 million investments for start of a product worldwide

At the end of January, 2021 the Neurent Medical company developing methods of treatment of chronic inflammatory diseases of a nose and nasal bosoms attracted $25 million during a round of financing of series B. The round was headed by the new investor of LSP with the LSP HEF-2 fund and also the Atlantic Bridge company investing from the Growth Fund IV fund. The Fountain Healthcare Partners company also took active part in this round of financing as the come-back investor.

The received means will be let to expansion of a clinical and business activity of the company which intends to get permission of regulatory bodies and to begin sales in the USA of the neyrolizny therapy of Neuromark Rhinitis Neurolysis Therapy for hospital treatment of chronic rhinitis. This widespread disease is characterized by resistant congestion of a nose, rinorey, sneezing and an itch in a nose. Chronic rhinitis considerably reduces quality of life and can have an adverse effect on sleep quality, mood and daily activity.

Technical director of Neurent Medical David Taunli (at the left) and CEO of Neurent Medical Brian Shields (on the right)

The system of neyrolizny therapy developed by Neurent Medical represents new option of treatment of chronic rhinitis. This system destroys the terminations of hyperactive parasympathetic nerves which are the cornerstone of chronic inflammation. Developers consider that unique design of the Neuromark system, functions of monitoring of a biological feedback and special algorithmic management tools will allow the doctor to influence at the same time several branches of a nerve with a fine precision, without breaking security and comfort of the patient.

The CEO and the cofounder of Neurent Medical Brian Shields thanked investors for a financial support and noted that it will help the company to enter international market.^[1]

Notes